Drugs / G250
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00203866 | Oct 2003 → Mar 2007 | renal cell carcinoma | University of Chicago | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00203866 ↗ |
| Action | Deplete | “Our hypothesis is that immunization with G250/Montanide/GM-CSF plus IL-2 can lead to an expansion of G250-specific CTL and result in killing of 0250 expressing micrometastatic RCC.” NCT00203866 ↗ |